D.E. Shaw & Co
XENE icon

D.E. Shaw & Co’s Xenon Pharmaceuticals XENE Stock Holding History

D.E. Shaw & Co’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
+19,800
New +$912K ﹤0.01% 3343

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co's XENE Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Xenon Pharmaceuticals (XENE) stake by 39% in Q1 2026, selling an estimated $549K and leaving 18,940 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3377.

D.E. Shaw & Co first reported a position in XENE in Q4 2018 and has held it in 30 quarters since. The position peaked at $14.8M in Q4 2021. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • D.E. Shaw & Co held 18,940 shares of Xenon Pharmaceuticals worth $1.1M as of Q1 2026.
  • D.E. Shaw & Co sold 11,911 Xenon Pharmaceuticals shares in Q1 2026, an estimated $549K.
  • Xenon Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3377 holding.
  • D.E. Shaw & Co first reported a position in Xenon Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • D.E. Shaw & Co's Xenon Pharmaceuticals position peaked at $14.8M in Q4 2021.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.